Pharmaceutical Supply for Licensed B2B Buyers

B2B product availability, documentation and quotation support

B2B Pharmaceutical Product Inquiry

Our portfolio includes oral tablets, injections and specialty pharmaceutical products. Product availability, documentation and quotation are provided upon qualified business inquiry. endogenous human GLP-1 hormone to regulate appetite centers and control food intake, achieving significant results in weight loss and blood sugar control, opening up new avenues for metabolic disease treatment.

View product
Request a Quote

Product Series

We offer a variety of product specifications to meet the treatment needs of different patients, ensuring efficacy and safety.

Product Features

GLP-1 Weight Loss Mechanism

GLP-1 is an important glucagon-like peptide that plays a wide range of physiological roles in the human body. Especially in patients with type 2 diabetes, GLP-1 has the ability to regulate blood sugar and improve metabolic function, making it an important drug in diabetes treatment.

GLP-1 hormone slows down gastric emptying, allowing food to stay in the stomach longer. This helps diabetic patients better control blood sugar, and can also control appetite by prolonging satiety, thereby creating a calorie deficit.

Learn More

Healthy Weight
Management

GLP-1’s Application in Weight
Control

Long-Acting Mechanism

Specially modified molecular structure significantly extends action time in the body, activating GLP-1 receptors.

Potent Blood Sugar Lowering Effect

Excellent ability to reduce HbA1c, superior to many other oral or injectable antidiabetic drugs.

Cardiovascular Benefits

Large cardiovascular outcome trials have proven significant reduction in major adverse cardiovascular events.

Significant Weight Loss Effect

Effectively reduces appetite, increases satiety, and decreases calorie intake, leading to significant and sustained weight loss.

Good Safety Profile

Most common adverse reactions are gastrointestinal, usually mild to moderate and temporary.

Multiple Specifications Available

Offers various dosage specifications, allowing doctors to flexibly adjust based on treatment goals and individual patient conditions.

Product Comparison

Semaglutide vs. Tirzepatide vs. Other Peptide Products: Providing comprehensive data comparison on weight loss, blood sugar reduction, and cardiovascular benefits.

FeatureSemaglutideTirzepatideOther Peptide Products
Cardiovascular BenefitsReduces risk of major adverse cardiovascular events 26%Potential cardiovascular benefits, clinical trials ongoingVaries by drug class; some show benefits, others do not
Weight LossSignificant weight loss 15-17%More potent weight loss 20-22.5%Variable, depends on drug class 5-10%
Dosing FrequencyOnce weekly injection (or daily oral)Once weekly injectionVaries (e.g., daily oral, weekly injection)
IndicationsType 2 Diabetes, ObesityType 2 Diabetes (Obesity indication under review)Type 2 Diabetes, Obesity, other metabolic conditions
Mechanism of ActionGLP-1 Receptor AgonistGIP and GLP-1 Receptor AgonistVaries (e.g., GLP-1, GIP, Amylin analogs)
Side EffectsNausea, vomiting, diarrhea, constipation (usually mild to moderate)Nausea, vomiting, diarrhea, constipation (similar to GLP-1 RAs, potentially more pronounced)Varies by drug class; common GI issues, potential for injection site reactions
Cost-EffectivenessHigh, but offers significant benefitsHigher than Semaglutide, reflects dual-agonist potencyVaries widely; some are very expensive, others more affordable

Product Advantages

High Purity Quality Assurance

Utilizing industry-leading biotechnology for production, with strict control from raw materials to finished products, maximizing the retention of active pharmaceutical ingredients to ensure excellent efficacy and high safety, safeguarding patient treatment.

Cost-Effective Choice

While maintaining uncompromised quality, we innovate pricing models to reduce patient treatment costs, demonstrating corporate social responsibility and making high-quality treatment accessible to more people.

Full-Spectrum Formulation

We offer a globally rare oral + injectable dual-formulation GLP-1 solution, covering the patient’s entire treatment cycle—Semaglutide tablets enhance convenience (no injection needed), while injectable forms ensure continuous blood sugar control and weight management. Tirzepatide is a dual-target (GIP/GLP-1) injectable, offering superior efficacy for severe metabolic diseases.

Multi-Target Precision Therapy

Our product portfolio includes both single-target (Semaglutide) and dual-target (Tirzepatide) GLP-1 therapies: Semaglutide: long-term blood sugar control (HbA1c ↓1.8-2.4%) + 26% cardiovascular risk reduction; Tirzepatide: achieves over 40% weight loss and metabolic improvement through dual GIP/GLP-1 activation.

Customer Trust & Reviews

Real feedback from medical professionals and patients, witnessing the quality and effectiveness of our products

Manager Zhang

"Vetion's Semaglutide injection has performed exceptionally in my clinical practice. Patients have shown significant improvements in blood sugar control and weight management. I am very satisfied with its quality and efficacy."

Coach Li

"After taking Vetion's Semaglutide tablets, my blood sugar has stabilized significantly and I've started losing weight. I feel much more energetic and healthier overall."

General Manager Wang

"Tirzepatide, as a dual-target agonist, shows great potential in metabolic disease treatment. Vetion's products are of high purity and efficacy, making them a trustworthy choice."

GLP-1 Frequently Asked Questions

Learn more about the mechanism of action, suitable populations, side effects, and precautions for GLP-1 drugs

GLP-1 (Glucagon-like peptide-1) receptor agonists are a class of drugs that mimic the GLP-1 hormone naturally secreted by the human intestine. By activating GLP-1 receptors, they promote insulin secretion (only when blood sugar is elevated), inhibit glucagon secretion, delay gastric emptying, and increase satiety, thereby lowering blood sugar and reducing weight.

GLP-1 drugs are primarily used to treat type 2 diabetes, helping patients control blood sugar and reduce glycated hemoglobin. In recent years, high-dose GLP-1 drugs have also been approved for the treatment of obesity or overweight adults with related complications to help them achieve significant weight loss.

The most common side effects are gastrointestinal, such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are usually mild to moderate and tend to decrease as treatment continues or the body adapts. The risk of severe hypoglycemia is low but increases when used in combination with sulfonylureas or insulin.

Semaglutide is a single GLP-1 receptor agonist that primarily acts through the GLP-1 pathway. Tirzepatide is a dual GIP (Glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that activates both intestinal hormone receptors simultaneously, typically showing more potent effects in blood sugar lowering and weight loss.

Unopened GLP-1 injectable drugs should generally be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and should not be frozen. After opening, some products can be stored at room temperature (below 30°C/86°F) for a certain period (usually 4 to 6 weeks), while others still require refrigeration. Always follow the specific storage instructions provided with the product.

GLP-1 drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They should also not be used in patients with a known hypersensitivity to any component of the drug. Pregnant and breastfeeding women should consult their healthcare provider before use.

Still Have Questions? Consult Our Experts

Our professional medical team can provide personalized medication advice and health guidance, answering any questions you have about Semaglutide oral tablets and other products.

Online Consultation
Online Consultation
Select your currency
USD United States (US) dollar
CNY Chinese yuan